Semnur Pharmaceuticals
SMNR · OTC
$0.40−$0.027 (−6.32%)TodayMarket closed ·
Prev close $0.427
Key indicators
SMNR profitability and balance sheet ratios
Return on equity 3.6% in Jun 2024, up 4.7 points on a year earlier.
| Period | Return on equity |
|---|---|
| Dec 2022 | -0.7% |
| Mar 2023 | -1.7% |
| Jun 2023 | -1.1% |
| Sep 2023 | -0.7% |
| Dec 2023 | 0.9% |
| Mar 2024 | 3.1% |
| Jun 2024 | 3.6% |
Income statement
No financial statements are reported for Semnur Pharmaceuticals.
Balance sheet
What the company owns and owes at period end
Total assets
Total liabilities
| Line item | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|
| Total assets | $9.0M | $9.1M | $0.6M |
| Total liabilities | $10.4M | $10.7M | $11.2M |
| Shareholder equity | −$1.4M | −$1.6M | −$10.6M |
| Cash and short-term investments | $0.0M | $0.0M | $0.0M |
| Total debt | $2.8M | $2.9M | $3.0M |
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.